FR2487198A1 - Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique - Google Patents
Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique Download PDFInfo
- Publication number
- FR2487198A1 FR2487198A1 FR8016582A FR8016582A FR2487198A1 FR 2487198 A1 FR2487198 A1 FR 2487198A1 FR 8016582 A FR8016582 A FR 8016582A FR 8016582 A FR8016582 A FR 8016582A FR 2487198 A1 FR2487198 A1 FR 2487198A1
- Authority
- FR
- France
- Prior art keywords
- fractions
- immuno
- substance
- protein
- isolation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 title abstract description 5
- 238000002955 isolation Methods 0.000 title description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims abstract description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims abstract description 4
- 102000005348 Neuraminidase Human genes 0.000 claims abstract description 4
- 108010006232 Neuraminidase Proteins 0.000 claims abstract description 4
- 102000004142 Trypsin Human genes 0.000 claims abstract description 4
- 108090000631 Trypsin Proteins 0.000 claims abstract description 4
- 238000000862 absorption spectrum Methods 0.000 claims abstract description 4
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 4
- 239000012588 trypsin Substances 0.000 claims abstract description 4
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims abstract 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims abstract 2
- 241000194046 Streptococcus intermedius Species 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 17
- 229940109357 desoxyribonuclease Drugs 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 8
- 238000001155 isoelectric focusing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241000186066 Actinomyces odontolyticus Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000589990 Campylobacter sputorum Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241001501603 Haemophilus aegyptius Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000123728 Leptotrichia buccalis Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 241000202889 Mycoplasma salivarium Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000588659 Neisseria mucosa Species 0.000 description 1
- 241001464937 Neisseria perflava Species 0.000 description 1
- 241001136170 Neisseria subflava Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 101800004910 Nuclease A Proteins 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000006928 Persicaria lapathifolia Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 241001135223 Prevotella melaninogenica Species 0.000 description 1
- 241001135261 Prevotella oralis Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606726 Rickettsia typhi Species 0.000 description 1
- 241000606583 Rodentibacter pneumotropicus Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607343 Vibrio cholerae O1 biovar El Tor Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950000550 sodium metrizoate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/822—Protozoa
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8016582A FR2487198A1 (fr) | 1980-07-28 | 1980-07-28 | Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique |
| DE8181401114T DE3164422D1 (en) | 1980-07-28 | 1981-07-09 | Immunosuppressive compound, process for isolating it and its therapeutical use |
| EP81401114A EP0045237B1 (fr) | 1980-07-28 | 1981-07-09 | Nouvelle substance immuno-suppressive, son procédé d'isolement et son application en thérapeutique |
| AT81401114T ATE8146T1 (de) | 1980-07-28 | 1981-07-09 | Immunosuppressivstoff, verfahren zu dessen isolierung und seine therapeutische anwendung. |
| US06/285,567 US4404194A (en) | 1980-07-28 | 1981-07-21 | Immuno-suppressive substance, its isolation process, and its therapeutic use |
| JP56118366A JPS57140792A (en) | 1980-07-28 | 1981-07-28 | Novel immunity control substance, isolation thereof and therapeutical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8016582A FR2487198A1 (fr) | 1980-07-28 | 1980-07-28 | Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2487198A1 true FR2487198A1 (fr) | 1982-01-29 |
| FR2487198B1 FR2487198B1 (OSRAM) | 1983-07-22 |
Family
ID=9244590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8016582A Granted FR2487198A1 (fr) | 1980-07-28 | 1980-07-28 | Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4404194A (OSRAM) |
| EP (1) | EP0045237B1 (OSRAM) |
| JP (1) | JPS57140792A (OSRAM) |
| AT (1) | ATE8146T1 (OSRAM) |
| DE (1) | DE3164422D1 (OSRAM) |
| FR (1) | FR2487198A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60188066A (ja) * | 1984-03-09 | 1985-09-25 | Akira Endo | 新コラゲナ−ゼ、デイスコリシン及びその製造法 |
| IL71683A0 (en) * | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
| JPH0669959B2 (ja) * | 1985-09-26 | 1994-09-07 | 東燃株式会社 | コレラ毒素類を活性成分とする免疫抑制剤 |
| US4876194A (en) * | 1986-07-22 | 1989-10-24 | Hightech Receptor Ab | Protein L and subfragments thereof, with immunoglobulin binding activity, a process for preparing thereof, reagent kit, pharmaceutical composition and a peptococcus magnus strain |
| US4746729A (en) * | 1986-07-30 | 1988-05-24 | Kuettner Klaus E | Cartilage-derived leukocyte elastase-inhibitor |
| NL8703107A (nl) * | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
| GB8919321D0 (en) * | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
| US5200344A (en) * | 1990-11-13 | 1993-04-06 | Blaser Martin J | Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens |
| AU7482694A (en) * | 1993-08-27 | 1995-03-21 | Enteric Research Laboratories, Inc. | (campylobacter jejuni) antigens, and methods for their production and use |
| WO1995024425A1 (en) * | 1994-03-11 | 1995-09-14 | Board Of Regents, The University Of Texas System | Immunomodulatory trichinella substances |
| AU5344996A (en) * | 1995-03-23 | 1996-10-08 | Governors Of Dalhousie College And University | A process of prolonging organ allograft survival |
| US6090413A (en) * | 1996-03-25 | 2000-07-18 | Lee; Timothy D. | Process of prolonging organ allograft survival |
| JP4261049B2 (ja) | 1997-10-08 | 2009-04-30 | アイソテクニカ インコーポレイテッド | 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用 |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| CN100334106C (zh) * | 2001-10-19 | 2007-08-29 | 伊索泰克尼卡股份有限公司 | 环孢菌素类似物的合成 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4056614A (en) * | 1972-09-22 | 1977-11-01 | Marc Bonneau | Immunity depressant medicine |
| US4117118A (en) * | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
| US4268434A (en) * | 1979-01-09 | 1981-05-19 | Higerd Thomas B | Immunosuppressive extracellular product from oral bacteria |
-
1980
- 1980-07-28 FR FR8016582A patent/FR2487198A1/fr active Granted
-
1981
- 1981-07-09 EP EP81401114A patent/EP0045237B1/fr not_active Expired
- 1981-07-09 DE DE8181401114T patent/DE3164422D1/de not_active Expired
- 1981-07-09 AT AT81401114T patent/ATE8146T1/de not_active IP Right Cessation
- 1981-07-21 US US06/285,567 patent/US4404194A/en not_active Expired - Fee Related
- 1981-07-28 JP JP56118366A patent/JPS57140792A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| CA1973 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0045237A1 (fr) | 1982-02-03 |
| DE3164422D1 (en) | 1984-08-02 |
| EP0045237B1 (fr) | 1984-06-27 |
| FR2487198B1 (OSRAM) | 1983-07-22 |
| ATE8146T1 (de) | 1984-07-15 |
| US4404194A (en) | 1983-09-13 |
| JPS57140792A (en) | 1982-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0045237B1 (fr) | Nouvelle substance immuno-suppressive, son procédé d'isolement et son application en thérapeutique | |
| Sveen | The capacity of lipopolysaccharides from Bacteroides, Fusobacterium and Veillonella to produce skin inflammation and the local and generalized Shwartzman reaction in rabbits | |
| DE3886175T2 (de) | Trigramin, ein Polypeptid, das die Aggregation der Blutplättchen hemmt. | |
| FR2552326A1 (fr) | Composition d'extrait soluble de pyridine et d'endotoxine detoxifiee raffinee et son utilisation | |
| WO1991016428A1 (fr) | Proteine associee a la pancreatite aigue, moyens pour le diagnostic de la pancreatite aigue | |
| Puhvel et al. | Cytotaxin production by comedonal bacteria (Propionibacterium acnes, Propionibacterium granulosum and Staphylococcus epidermidis) | |
| FR2466991A1 (fr) | Perfectionnement a la preparation d'allergene | |
| EP0101063A2 (de) | Neues Polypeptid mit Wirkung auf das Immunsystem, Verfahren zu seiner Isolierung und Reinigung, seine Verwendung und dieses enthaltende Mittel | |
| FR2560212A1 (fr) | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps | |
| EP0208743B1 (de) | POLYDISPERSE NATIVE PSEUDOMONAS-FLAGELLA(H)-ANTIGENE (FAg) UND VERFAHREN ZU IHRER GEWINNUNG | |
| FR2515518A1 (fr) | Procede de production de preparations immunobiologiques applicables pour le diagnostic, la prevention et/ou le traitement d'infections par le candida guilliermondii, et preparations immunobiologiques en resultant | |
| FR2550802A1 (fr) | Procede de production d'interleukine 1 humaine et medicaments correspondants | |
| FR2543970A1 (fr) | Anticorps vis-a-vis de champignons du genre aspergillus | |
| FR2586814A1 (fr) | Anticorps monoclonaux anti-proteines p 27 k et p 31 k de prosomes et leur application a titre de reactifs de diagnostic et/ou d'identification de cellules | |
| Babejr et al. | PYODERMA GANGRENOSUM ASSOCIATED WITH ANTIHOSPHOLIPID ANTIBODIES. | |
| FR2597107A1 (fr) | Tripeptide doue d'une activite immunostimulante | |
| JPH088873B2 (ja) | ヒト癌壊死因子の製造法 | |
| EP0243390A1 (fr) | Nouvelle proteine de mammifere ayant une activite immunomodulatrice et progestative. | |
| Sprince | The Nutrition of Protozoa: III. An Improved Procedure for Separating Human Blood Serum into the Two Fractions Essential for the Sustained Growth of Trichomonas vaginalis | |
| EP0613484A1 (fr) | Produit bactericide, composition pharmaceutique le contenant et additif alimentaire | |
| FR2641538A1 (fr) | Facteur inhibiteur du complement, sa caracterisation et ses applications | |
| DE19728834C2 (de) | Eisenreduktase | |
| Sato et al. | Wax D fraction of an unclassified mycobacterium strain | |
| JPH07116232B2 (ja) | 新規なポリペプチド及び該ポリペプチドを含有する抗菌剤 | |
| JPS5837835B2 (ja) | 微生物リポプロテインリパ−ゼｍａ−４６ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |